Literature DB >> 29700570

[The new S3 guideline "Prevention of cervical carcinoma" : What is important for pathology?]

D Schmidt1.   

Abstract

Of the numerous aspects involved in the diagnosis, treatment, and follow-up of cervical uterine precursor lesions, epidemiology, virology, cytology, human papillomavirus (HPV) testing, and diagnostic algorithms for equivocal and HPV-positive findings are important for pathologists. Cytology will continue to be used as a preventive medical check-up in young women, while HPV-based screening is suggested for older women. HPV screening has yielded a significant reduction in cancer precursors and invasive cervical carcinoma in numerous studies. In contrast to the sensitivity, the specificity of the HPV test is inferior to that of cytology and the morphological biomarker p16/Ki-67, so that they are suitable as methods in the triage of HPV-positive findings. Cytological abnormalities and mildly dysplastic changes could be further clarified by an HPV test or the p16/Ki-67 test. The HPV test should also be used in the follow-up of patients after conization.

Entities:  

Keywords:  Biomarkers; Cytology; HPV DNA test; HPV-16; Ki-67 antigen

Mesh:

Substances:

Year:  2018        PMID: 29700570     DOI: 10.1007/s00292-018-0441-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  12 in total

1.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.

Authors:  Teresa M Darragh; Terence J Colgan; J Thomas Cox; Debra S Heller; Michael R Henry; Ronald D Luff; Timothy McCalmont; Ritu Nayar; Joel M Palefsky; Mark H Stoler; Edward J Wilkinson; Richard J Zaino; David C Wilbur
Journal:  Arch Pathol Lab Med       Date:  2012-06-28       Impact factor: 5.534

Review 2.  Liquid compared with conventional cervical cytology: a systematic review and meta-analysis.

Authors:  Marc Arbyn; Christine Bergeron; Paul Klinkhamer; Pierre Martin-Hirsch; Albertus G Siebers; Johan Bulten
Journal:  Obstet Gynecol       Date:  2008-01       Impact factor: 7.661

3.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

4.  p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study.

Authors:  Dietmar Schmidt; Christine Bergeron; Karin J Denton; Ruediger Ridder
Journal:  Cancer Cytopathol       Date:  2011-03-25       Impact factor: 5.284

5.  A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer.

Authors:  Michael Herfs; Yusuke Yamamoto; Anna Laury; Xia Wang; Marisa R Nucci; Margaret E McLaughlin-Drubin; Karl Münger; Sarah Feldman; Frank D McKeon; Wa Xian; Christopher P Crum
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-11       Impact factor: 11.205

6.  Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions.

Authors:  Michael Herfs; Carlos Parra-Herran; Brooke E Howitt; Anna R Laury; Marisa R Nucci; Sarah Feldman; Cynthia A Jimenez; Frank D McKeon; Wa Xian; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2013-09       Impact factor: 6.394

Review 7.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.

Authors:  Marc Arbyn; Peter Sasieni; Chris J L M Meijer; Christine Clavel; George Koliopoulos; Joakim Dillner
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

8.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

Authors:  Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Oncol       Date:  2010-10-15       Impact factor: 41.316

Review 9.  Biological agents.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  2012

10.  Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.

Authors:  Hans Ikenberg; Christine Bergeron; Dietmar Schmidt; Henrik Griesser; Francisco Alameda; Claudio Angeloni; Johannes Bogers; Roger Dachez; Karin Denton; Jalil Hariri; Thomas Keller; Magnus von Knebel Doeberitz; Heinrich H Neumann; Luis M Puig-Tintore; Mario Sideri; Susanne Rehm; Ruediger Ridder
Journal:  J Natl Cancer Inst       Date:  2013-10-04       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.